[ad_1]
The British-Swedish pharmaceutical company AstraZeneca and the University of Oxford announced that they are working on a new vaccine, specifically against the Omicron variant.
The vaccine belongs to the class of adenoviruses, a weakened virus that enters the individual’s DNA and causes diseases that are easy to create antibodies to protect against the real virus.
Sandy Douglas, an Oxford scientist, said the adenovirus-class vaccines “could in principle be applied to any new variant sooner than previously thought.”
According to a study published in the medical journal The Lancet, protection from the current AstraZeneca vaccine begins to weaken 3 months after the second dose. The study comes as requests from citizens to take the third dose have increased, amid the rapid spread of the Omicron variant.
Israel meanwhile announced it would start giving the fourth dose. According to an advisory group in Israel, the fourth dose will be given to people over 60 years old. It can be given four months after the third dose.
Israel has been ahead of other countries in the vaccination campaign of its citizens.voa
top channel
[ad_2]
Source link
